January 19, 2009 - The American Society of Breast Disease Pathfinder Lectures will honor Marie Overgaard, M.D., and Steve H. Parker, M.D. as part of the Society’s Annual Symposium, April 2-4, 2009, in Chicago, IL. In announcing the recipients of the Society’s only honorary recognition, American Society of Breast Disease president Julio A. Ibarra, M.D., noted that "through their vision and work this year’s honorees - Marie Overgaard and Steve H. Parker - have established new standards in diagnosis and treatment that have benefited the lives of millions of women around the world." Marie Overgaard, M.D., professor at Aarhus Hospital in Denmark, is the ASBD's 2009 Pathfinder Lecturer in Radiation Oncology. Her work in leading the large randomized trials of the Danish Breast Cancer Cooperative Group dramatically reshaped the hypothesis of breast cancer as a systemic disease. Through her research, Dr. Overgaard showed that post-mastectomy radiation with chemotherapy in both pre- and post-menopausal women positively impacted survival. Her studies of postoperative radiotherapy have earned her recognition as an honorary fellow in the American College of Radiology and the Gold Medal Award of the American Society for Radiation Oncology. The honoree for the 2009 ASBD Pathfinder Lecturer in Radiology is interventional radiologist Steve H. Parker, M.D., who is well known in the field of breast diagnosis. Dr. Parker has been a pioneer in the development and study of minimally invasive biopsy. His innovations have included stereotactic-guided core biopsy, ultrasound-guided core biopsy, stereotactic-guided vacuum assisted biopsy (VAB), ultrasound-guided VAB, ultrasound-guided sentinel node core biopsy/VAB and ultrasound-guided percutaneous excision of masses. While serving at Fitzsimons Army Medical Center, Dr. Parker developed the first use of image-guided percutaneous breast biopsy with a large-core needle. He was the principal author of a multi-institutional study showing that stereotactic and ultrasound large-core breast biopsy is as accurate as surgical biopsy. Dr. Parker further refined this technique by helping to develop additional minimally invasive tools, including VAB devices. Dr. Parker was the course director of the “Breast Imaging and Intervention in the 21st Century” international breast conference for 10 years and has lectured worldwide for the past two decades. Source: American Society of Breast Disease For more information: www.asbd.org
Society Honors Innovators in Breast Cancer Radiology, Radiation Therapy
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the x, y and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.
A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. Image courtesy of Xiandoing Xue, UC Davis